Navigation Links
Large Study of Lacrisert(R) Dry Eye Insert:

Patients Experience Significant Improvement in Ocular Surface Disease and Quality of Life

LAWRENCEVILLE, N.J., May 4 /PRNewswire/ -- Aton Pharma, Inc. announced today that results from a large (n = 520) multi-center patient registry study of its Lacrisert(R) ophthalmic insert will be presented this week during the 2009 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 3-7, Ft. Lauderdale, FL, and later in the month at the 145th Annual Meeting of the American Ophthalmological Society (AOS), May 14 -17, Half Moon Bay, CA. Lacrisert (hydroxypropyl cellulose ophthalmic insert) is a preservative-free, once-daily*, sustained release prescription insert indicated for moderate to severe dry eye, that helps to retain moisture, stabilize the tear film, and lubricate the eye.

"This is the first major study of Lacrisert to be undertaken in more than two decades," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "Our commitment to expanding product availability and increasing physician awareness and knowledge of Lacrisert includes gathering of key efficacy data such as through this study."

The multicenter, 2-visit, open label, 4-week study was conducted to determine both physician and patient acceptability and ease of use of Lacrisert in adult patients with a history of dry eye syndrome. It was hypothesized that patients would experience improvements in their overall quality of life as well as in measures of dry eye signs and symptoms. A patient registry study is designed to examine a wide range of correlations and show predictive relationships, providing a rich resource of data to mine over time.

Bruce H. Koffler, M.D., will present data from the study in a poster at the 2009 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), "Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert) Significantly Improves Symptoms of Dry Eye Syndrome and Patient Quality of Life" (Bruce H. Koffler for the LAC-07-01 Study Group, poster 4660/D904, Wednesday, May 6, 1:45-3:30 PM).

As reported by Dr. Koffler, mean ocular surface disease index (OSDI) total scores for patients in the study significantly improved by more than 25% over the four weeks of the study; this was over and above any improvement patients may have gained from previous dry eye therapies administered before the study.

Treatment with Lacrisert also resulted in significant improvement in mean occurrence of discomfort in heated areas (P < 0.0001) and significant improvements when performing housework (P = 0.0018). Patients reported significant reductions in mean severity of DES symptoms (P < 0.0001). The most commonly reported adverse event leading to discontinuation was blurred vision, observed in 8.7% of patients.

"The study shows use of Lacrisert results in significant improvements in DES symptoms, in activities of daily living, and in patient quality of life," explained Dr. Koffler.

A second poster at the 2009 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) based on the patient registry study, "Effect of Lacrisert(R) on the Signs and Symptoms of Dry Eye in Contact Lens Wearers" (Wednesday, May 06, 2009, 1:45 PM - 3:30 PM, Hall B/C) will be presented by Stephen J. Curwen et al of Ophthalmic Research Associates (ORA). This poster focuses on a sample subset of 30 contact lens wearers with a history of dry eye.

The 30 contact lens patients reported significant improvements in dryness (P = < 0.0001) and grittiness (P = 0.008) after 4 weeks of dosing with Lacrisert when compared to baseline. Mean TFBUT increased from 2.98 to 4.08 sec. (P < 0.0001) and mean corneal/conjunctival staining decreased from 1.21 to 0.79 units (P < 0.0001). Investigators reported that 70% of subjects experienced an improvement of dry eye symptoms and 53% experienced an improvement in dry eye signs while wearing contact lenses. It was also reported that Lacrisert was longer lasting 93% of the time when compared to rewetting solutions.

"The data in this study show that Lacrisert relieves the signs and symptoms of dry eye in contact lens wearers with a history of dry eye," concluded the ORA investigators. "Patients experienced significant improvements in tear film stability as well as ocular surface damage. Lacrisert may be longer-lasting than other available treatments."

American Ophthalmological Society (AOS)

Marguerite McDonald, M.D., F.A.C.S., will present additional data from the study in a presentation at AOS, "LACRISERT(R) (hydroxypropyl cellulose ophthalmic insert) Reduces the Signs and Symptoms of Dry Eye Syndrome (DES) and Improves Patient Quality of Life" (Marguerite McDonald, Gerard D'Aversa, Henry Perry, John Wittpenn and Eric Donnenfeld for the LAC-07-01 Study Group, Saturday, May 16).

Dr. McDonald reports that patients experienced significant improvements in discomfort, burning, dryness, grittiness, stinging, and light sensitivity (P < 0.0001) after 4 weeks of treatment with Lacrisert. Overall, 57% of subjects experienced an improvement of dry eye symptoms and 54% in clinical signs (including Schirmers Test, conjunctival staining and TFBUT).

"The study shows Lacrisert significantly reduces symptoms and clinical signs of moderate to severe dry eye, which is borne out by my own clinical experience as well," stated Dr. McDonald.

Registry Study Methodology

In the Lacrisert study, at visit 1, patients (n = 520) were given a general dry eye evaluation, screened by slit-lamp biomicroscopy and best corrected visual acuity, and were required to fill out a questionnaire that included the ocular surface disease index (OSDI), a validated measure of quality of life. Patients were trained on the proper insertion and use of the insert. Patients were contacted by telephone on Day 3 of the study for follow up and reinstruction. At visit 2 (Week 4), patients were given a clinical evaluation and required to complete a second evaluation. Answers provided on questionnaires (scored on Likert-type scales) were used to determine changes in patient-reported outcomes such as symptoms and quality of life.

About Lacrisert

Lacrisert has been FDA-approved for use in patients with moderate to severe dry eye and available by prescription for more than two decades. Unlike artificial tear substitutes that have a residence time measured in minutes, Lacrisert provides continual lubrication and protection to the surface of the eye for all-day relief. Lacrisert acts to stabilize and thicken the pre-corneal tear film and prolong the tear film breakup time, which is usually accelerated in patients with dry eye states. Information and educational video content are available at

Most adverse reactions with Lacrisert were mild and transient and included transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids and hyperemia. Lacrisert should not be used by patients who are hypersensitive to hydroxypropyl cellulose. If improperly placed, Lacrisert may result in corneal abrasion.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of ten products, with sales in over 30 countries, focuses on ophthalmic diseases, orphan conditions and acute care hospital products. For more information, see

* Some patients may require the flexibility of twice-daily dosing for optimal results.

SOURCE Aton Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Women live longer, not better, largely because of obesity and arthritis
2. Youth to Fight Obesity With Worlds Largest Exercise Class
3. Schering-Plough Flips the Switch on 1.7 MW Rooftop Solar Panel System, One of the Largest in N.J., North America
4. Worlds largest DNA scan for autism uncovers new gene variant for disorder
5. Less Than a Year After CDC Announced the U.S. HIV Epidemic Is Much Larger Than Previously Thought, Publics Sense of Urgency Is Down, Even Among Some Higher Risk Groups
6. Ohio Health Care Association/Ohio Centers for Assisted Living Host Midwests Largest Long-Term Care Convention in Columbus
7. Largest Organ and Tissue Donation Event in U.S.: Seventh Annual Donate Life Run/Walk & Family Festival, Sat., April 25 at Cal State Fullerton
8. Michigan Blues Launch Nations Largest Program for Patient-Centered Medical Home
9. Large congenital and solitary intrahepatic arterioportal
10. Los Angeles Area Non-Profit OneLegacy Grows Into Worlds Largest Tissue Recovery Organization
11. Blue Cross Launches Largest Selection of Individual Plans Available in Minnesota
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
(Date:11/30/2015)... ... November 30, 2015 , ... A record crowd gathered at the ... organized by the Baruch S. Blumberg Institute. , The institute, which is the research ... science and biotechnology leaders for the conference, which focused on ways companies can work ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of antimicrobials ... effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial ... small molecule analogs that target the functions of SecA, a central part of ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... ... top choice for innovative, patient centered orthopedic care. Led by John Vitolo, ... your injury or chronic condition, the team at Advocare Orthopedic & Sports Medicine ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... specializes in general dentistry out of Glen Ridge, NJ. He has both ... to achieve optimal mastication. He is also an expert in cosmetic dentistry. ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 Diplomat Pharmacy, Inc. (NYSE: ... the Detroit Free Press as a Top Workplace , ... to work for in 2015. ... 100 winners annually, based on employee surveys rating company leadership, ... Workplaces are based solely on employee feedback. The survey is ...
(Date:11/30/2015)... , Nov. 30, 2015  IBA Molecular North America, ... distribution of radiopharmaceuticals, announced that as of January 1, ... (Zevacor Pharma). The decision to rebrand the company reflects ... as well as its close relationship with Zevacor Molecular.  ... Health and Science (IHS). Peter Burke ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology: